Transforming the pharmaceutical industry: Operational models, digitalization, and capabilities for the future

The pharmaceutical industry is undergoing a period of profound changes. Extraordinary advances in biotechnology, advanced therapies, personalized medicine, and digital tools have marked the last decade. However, it has also exposed the weaknesses in how organizations are structured. Regulatory pressure is increasing, product lifecycles are shortening, healthcare system expectations are rising, and the need to accelerate innovation has become unavoidable.

In this context, success will depend on companies’ ability to strategically adopt digital technologies, simplify operational models and processes, build capabilities that sustain increasingly complex portfolios, and strategically embrace digital technologies.

The urgency of transformation in the pharmaceutical industry

The pharmaceutical industry operates in one of the most demanding and dynamic regulatory environments in the world. The proliferation of legal requirements, constant audits, and the need to ensure full traceability create additional layers of complexity that directly impact decision-making speed and operational efficiency. Historically, heavy organizational models with multiple interfaces and functional dependencies have prolonged approval cycles and hindered the ability to respond to market changes or regulatory updates, such as those associated with benefit and price evaluation regimes.

At the same time, pressure to reduce costs, ensure rapid market access, and demonstrate clinical value is intensifying. This context demands a level of agility that many organizations are still struggling to achieve.

The convergence of operational efficiency, innovation, and talent

The transformation needed in the pharmaceutical industry is not limited to technological modernization; it requires a strategic alignment between operational efficiency, continuous innovation, and talent development. As new therapeutic modalities, digital platforms, and artificial intelligence tools become central to competitiveness, companies need leaner processes, data-driven approaches, and employees with specialized skills.

On the one hand, improving operational efficiency demands standardized work models, transparent information flows, and systems that support evidence-based decision-making. On the other hand, innovation relies on the ability to investigate, experiment, and adapt quickly—something achievable only with agile, digitally empowered multidisciplinary teams.

Thus, true competitive advantage emerges from the integration of these three elements: optimized processes, advanced technology, and talent equipped to operate in a highly complex scientific and digital context. This strategic triangle defines the new paradigm of the pharmaceutical industry and underscores the urgency for transformation.

Simplifying complex operational models in the pharmaceutical industry

Pharmaceutical companies have grown over decades through successive organizational layers designed to meet strict regulatory requirements and the geographical spread of markets. The result has been the creation of highly matrixed structures, with multiple hierarchical levels and functional areas that sometimes duplicate responsibilities. Studies show that up to 30% of work time in pharmaceutical operations can be consumed by administrative and compliance tasks, significantly reducing operational agility.

While this model ensures compliance, it compromises speed, accountability, and efficiency—three essential pillars in a sector under pressure from pricing reforms, more demanding therapeutic value assessments, and increasingly shorter response cycles.

Operational simplification requires structural interventions such as:

• Streamlining hierarchical levels and decision chains, adjusting spans of control to increase the speed and quality of decision-making.
• Optimizing management processes and operational visibility, eliminating micromanagement practices, and reducing non-value-added tasks.
• Effective integration between global, regional, and local structures, mitigating redundancies, reinforcing strategic coherence, and enabling decisions closer to market realities.
• Optimizing and standardizing core processes, ensuring leaner workflows, greater predictability, and systematic waste elimination.
• Increasing team autonomy, creating conditions for faster problem resolution, continuous improvement, and end-to-end accountability for results.

Organizational transformation consists of reconfiguring the decision-making system so that information flows quickly, in compliance, but without the rigidity that has historically delayed innovation. Countries like Germany (via AMNOG), Japan, and the U.S. continue to tighten economic evaluation and price review mechanisms, making rapid responses a strategic imperative.

Enhancing R&D and operational efficiency with AI and digital technologies

The growing complexity of therapeutic modalities, the pressure to accelerate development timelines, and the need to strengthen operational reliability have made it clear that traditional digital models are no longer sufficient. The pharmaceutical industry collects vast amounts of data (clinical, laboratory, production, quality, and supply chain), but the way this data is organized, analyzed, and converted into decisions remains fragmented and slow. This reality directly impacts R&D productivity, process stability, and the ability to respond to fluctuations in demand or emerging regulatory requirements.

To overcome these challenges, pharmaceutical companies are transitioning to a digital-first model, where AI and automation play a central role in eliminating waste, reducing administrative burden, and enhancing process robustness. The priority is to unlock speed and predictability by creating systems that are less dependent on manual tasks and more data-driven. It is estimated that generative AI alone could generate between $60 billion and $110 billion in annual value in the industry.¹

Thus, digital transformation in the pharmaceutical industry is manifested in three main areas, as described below.

Restructuring R&D activities through advanced analytics

Integrating AI into the discovery phase, pre-clinical development, and clinical trial design allows:

• Consolidating laboratory data and historical molecular data to support process design decisions.
• Accelerating safety and efficacy analysis, reducing experimentation cycles.
• Automating regulatory documentation and generating protocols with less variability.
• Minimizing human errors and shortening times to critical development milestones.

These advancements significantly reduce manual effort in R&D and increase the likelihood of technical success throughout the development stages.

Optimizing operations and quality through smart systems

Incorporating AI into production processes enhances operational stability by:

• Anticipating equipment failures based on historical patterns.
• Supporting technical investigations and reducing diagnostic time in critical processes.
• Automating reports, deviation analysis, and quality documentation preparation.
• Reinforcing process consistency and reducing variability between shifts and equipment.

This reinforcement of operational discipline results in fewer deviations, more stable processes, and increased equipment efficiency (OEE).

Strengthening supply chain resilience with data-driven decisions

The pharmaceutical supply chain is highly sensitive to disruptions, whether from demand variations, supplier delays, or regulatory changes. Integrated digital systems and AI allow:

• End-to-end visibility of inventory levels, production, and lead times.
• Increased forecasting accuracy and adjustment of parameters in near real-time.
• Identification of emerging risks (logistical, geopolitical, environmental) and anticipation of contingencies.
• Automation of planning tasks, enhancing the analytical capacity of the planner.

The result is a more agile logistics system, capable of minimizing disruptions, avoiding stock excess, and reducing operational costs.

Digitalization and AI in the pharmaceutical industry can be profound transformation mechanisms when aligned with Kaizen principles, which are essential to sustain the competitiveness of the pharmaceutical industry.

Building distinctive capabilities through talent and strategic partnerships

The accelerated evolution of biomedical science, driven by new therapeutic modalities, digital discovery platforms, new production models, and advanced AI tools, is redefining the skill set required to compete in the pharmaceutical sector. However, many organizations are still structured around traditional capabilities designed to support more stable and predictable development and manufacturing models. This mismatch between future needs and current resources leads to limitations in innovation speed, the adoption of emerging technologies, and the ability to execute more agile operational models. Less than a third of pharmaceutical leaders believe their companies currently possess the necessary talent and capabilities to sustain future portfolios.² In other words, there is a skills gap in the face of the upcoming scientific-digital paradigm.

Companies must precisely identify which capabilities they should develop internally, which can be acquired through partnerships, and which should be accelerated through training or technology adoption. This process is a critical condition to ensure resilience and competitiveness in the medium to long term.

Building distinctive capabilities in the pharmaceutical industry typically revolves around three main pillars, as described below.

Reskilling and evolving internal teams

Digital and scientific transformation demands more multidisciplinary profiles, capable of working at the intersection of biology, engineering, data, and emerging technologies. This implies:

• Strengthening skills in bioinformatics, data science, laboratory automation, and AI-based modeling.
• Equipping operations and quality teams with knowledge of intelligent systems, algorithm interpretation, and decision-making in digital contexts.
• Developing leadership to promote a culture of continuous improvement, manage agile teams, navigate more decentralized decisions, and work in highly demanding collaborative technical models.

Internal development is essential because it enables companies to build unique, differentiating knowledge, reducing external dependencies in key areas.

Partnership ecosystems to accelerate innovation

The pace of innovation is too fast to be sustained solely by internal capabilities. The most successful companies build collaborative ecosystems that provide quick access to scientific expertise, new technologies, and flexible capabilities. It’s no coincidence that it is estimated that over 70% of the revenues from new drugs (New Molecular Entities – NMEs) since 2018 have originated from externally developed products.³ Key strategic partners include:

• Biotech start-ups and scale-ups, with strong specialization and short innovation cycles.
• Universities, research institutes, and hospitals, which provide access to cutting-edge scientific knowledge and clinical platforms.
• Technology providers and digital companies are essential for scaling AI, automation, and data solutions.
• CDMOs (Contract Development and Manufacturing Organizations), which provide industrial capacity and technical-operational expertise, accelerating technology transfers and production industrialization.

These partnerships function as natural extensions of the organization, allowing rapid progress in areas where building internally would be too slow or costly.

Strategic combination of build, buy, and collaborate

Building distinctive capabilities requires clear decisions on where to compete and where to cooperate. In practice, many companies already choose to outsource non-core activities. Large pharmaceutical companies outsource about 50% of their R&D activities, and some smaller biotechs even outsource 100% of their production.⁴ To do so, it is necessary to:

• Identify core capabilities that must be developed internally within the company.
• Determine support competencies that can be obtained through hiring, outsourcing, or technological solutions.
• Ensure the organization retains control and depth in critical areas for differentiation, such as R&D, clinical understanding, quality, and process technology.

This hybrid approach ensures that the company remains agile, innovative, and able to respond to market needs and its pipeline quickly. Together, these three pillars allow pharmaceutical companies to build a solid foundation for the future. The development of capabilities is a strategic engine that drives innovation, accelerates execution, and strengthens competitive advantage in a sector where technical knowledge, speed, and adaptability are key.

Conclusion: The pharmaceutical industry as an integrated ecosystem of innovation and continuous improvement

The pharmaceutical industry is evolving into a true integrated ecosystem of innovation, where science, technology, talent, and operations work in coordination to address increasingly demanding challenges. The simplification of operational models, the strategic adoption of AI and digital solutions, and the development of distinctive capabilities are not isolated initiatives; they represent complementary pillars of a structural transformation that is redefining how the sector creates value.

In an environment marked by regulatory pressures, demand volatility, technological complexity, and increasing competition, the organizations that will thrive are those capable of:

• Reducing organizational complexity to accelerate decision-making.
• Valuing data as a strategic asset, creating more predictable, robust, and efficient processes.
• Cultivating multidisciplinary talent, ready to work with new technologies and highly demanding collaborative models.
• Establishing smart partnerships, expanding scientific, operational, and technological capabilities.
• Promoting a culture of continuous improvement within the pharmaceutical industry, where every team actively contributes to optimizing processes, eliminating waste, and sustaining innovation.

In this new phase, operational excellence and scientific excellence become inseparable. Only with simplified models, mature digital capabilities, and teams prepared to improve every day will it be possible to accelerate the development of transformative therapies and ensure that they reach patients with quality, speed, and sustainability.

The pharmaceutical industry of the future will inevitably be more agile, more collaborative, and more intelligent: a living ecosystem of innovation, supported by continuous improvement as a central management principle.

References

1. Shah, B., Viswa, C. A., Zurkiya, D., Leydon, E., & Bleys, J. (2024, January 9). Generative AI in the pharmaceutical industry | McKinsey McKinsey & Company. ↩︎
2. McKinsey & Company. (2020). Simplification for success: Rewiring the biopharma operating model | McKinsey ↩︎
3. Van de Vyver, B., Berghauser Pont, L., Parekh, R., Smietana, K., & Robke, L. (2025, January 9). Biopharma dealmaking to boost R&D productivity | McKinsey McKinsey & Company. ↩︎
4.  Weaver. (2025, March 31). Optimizing Quality Through Pharma Outsourcing | Weaver Weaver. ↩︎